Jump to content

Talk:Mirabegron

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Cewbot (talk | contribs) at 07:07, 6 February 2024 (Maintain {{WPBS}} and vital articles: 2 WikiProject templates. Create {{WPBS}}. Keep majority rating "Start" in {{WPBS}}. Remove 2 same ratings as {{WPBS}} in {{WikiProject Pharmacology}}, {{WikiProject Medicine}}.). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Prevalence of prescription and use

[edit]

If 43% of US women have been diagnosed with OAB, what is the current prevalence of prescription and use of Myrbetriq® (mirabegron) among US women? MaynardClark (talk) 00:55, 29 October 2018 (UTC)[reply]

  1. Myrbetriq [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.
  2. Astellas. Myrbetriq. Data on File.
  3. Federal Aviation Administration. Federal Air Surgeon’s Medical Bulletin. Oklahoma City, OK: Federal Aviation Administration. 2013‑2014;51(4):6.

MaynardClark (talk) 00:55, 29 October 2018 (UTC)[reply]